Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 5:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: secukinumab (AIN457) Clear all
Completed Phase 3 Interventional Results available

This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Birmingham, Alabama • Rogers, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 6, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

NCT02745080
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Adalimumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
19
States / cities
Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

NCT03668613
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01640951
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 6, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

NCT01095250
View directory record Official record
Conditions
Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
5
States / cities
Beverly Hills, California • Cambridge, Massachusetts • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 6, 2026, 5:01 PM EDT
Terminated Phase 3 Interventional Results available

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

NCT04181762
View directory record Official record
Conditions
Lupus Nephritis
Interventions
secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

NCT03259074
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Mesa, Arizona • Escondido, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

NCT01071252
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
San Diego, California • Louisville, Kentucky • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double Blind, Placebo-controlled, Study of the Safety, Tolerability and Pharmacokinetics of AIN457 in Rheumatoid Arthritis Patients

NCT00669942
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Anniston, Alabama • Tucson, Arizona • Largo, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

NCT00770965
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 6, 2026, 5:01 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

NCT06130540
View directory record Official record
Conditions
Giant Cell Arteritis, Polymyalgia Rheumatica
Interventions
Secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Boca Raton, Florida • Zephyrhills, Florida • Willowbrook, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

NCT05767034
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Extension in AS: Sustainability of Benefits, Safety and Tolerability

NCT01863732
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo (Pbo)
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

NCT00809159
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
secukinumab (AIN457), placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Vestavia Hills, Alabama • Peoria, Arizona • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

NCT03350815
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 6, 2026, 5:01 PM EDT
Completed Phase 3 Interventional Results available

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

NCT01989468
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 6, 2026, 5:01 PM EDT